title: Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
abstract: The vaccination program in Zambia includes one dose of measles vaccine at 9 months of age. The objective of this study was to compare the cost-effectiveness of the current one-dose measles vaccination program with an immunization schedule in which a second dose is provided either through routine health services or through supplemental immunization activities (SIAs). We simulated the expected cost and impact of the vaccination strategies for an annual cohort of 400,000 children, assuming 80% vaccination coverage in both routine and SIAs and an analytic horizon of 15 years. A vaccination program which includes SIAs reaching children not previously vaccinated would prevent on additional 29,242 measles cases and 1462 deaths for each vaccinated birth cohort when compared with a one-dose program. Given the parameters established for this analysis, such a program would be cost-saving and the most cost-effective vaccination strategy for Zambia.
authors.affiliation: Centers for Disease Control and Prevention, National Immunization Program, 1600 Clifton Road, Mailstop E-61, Atlanta, GA 30333, USA. gdayan@cdc.gov
authors.forename: Gustavo H
authors.initials: GH
authors.lastname: Dayan
authors.forename: Lisa
authors.initials: L
authors.lastname: Cairns
authors.forename: Nalinee
authors.initials: N
authors.lastname: Sangrujee
authors.forename: Anne
authors.initials: A
authors.lastname: Mtonga
authors.forename: Van
authors.initials: V
authors.lastname: Nguyen
authors.forename: Peter
authors.initials: P
authors.lastname: Strebel
mesh_terms: D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006760:Hospitalization; D006801:Humans; D007117:Immunization, Secondary / Q000191:economics; D007223:Infant; D032541:Mass Vaccination / Q000191:economics*; D008457:Measles / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology; D016896:Treatment Outcome; D015024:Zambia / Q000453:epidemiology
chemical_list: D008458:Measles Vaccine